How are you using CYP2C19 genotyping for determining dual antiplatelet therapy for stroke?  

We are currently using it only as part of a study ongoing in our center. We use CYP2C19 on all participants who will need DAPT. In intermediate metabolizers (since there is equipoise), we get P2Y. Given that the genotyping results take a few days to come back, to guide our time-sensitive decision - ...

In my practice, P2Y12 assays are the primary tool I rely on for guiding dual antiplatelet decisions. They are more widely available across clinical settings, whereas CYP2C19 genotyping requires infrastructure that is not always accessible outside of large academic and tertiary centers. CYP2C19 ident...